

Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab)

Catalog # APR11557

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P16410 & Q9NZQ7
Reactivity	Human
Clonality	Bispecific
Isotype	VHH-VHH-Fc

Additional Information


Target/Specificity	CTLA-4 / CD152,B7-H1 / PD-L1 / CD274
Expression system	CHO

Protein Information

Images




Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 97.11%, determined by SEC-HPLC.


Erfonrilimab bound to CTLA4 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Erfonrilimab bound in human CTLA4 Protein-His, and the EC50 was 0.010 nM.




Erfonrilimab bound to PD-L1 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Erfonrilimab bound in human PD-L1 Protein-His, and the EC50 was 0.012 nM.




Erfonrilimab bound to huCTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Erfonrilimab bound to huCTLA4-CHO-K cells, and the EC50 was 14.510 nM.




Erfonrilimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Erfonrilimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.759 nM.



Co-incubation of Erfonrilimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Erfonrilimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.681 nM.



The detected molecular weight of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 107.14 kDa.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.